An extraordinary and exciting meeting was co-organized by the American Association for Cancer Research and the Swiss Institute for Experimental Cancer Research in Lausanne.
This meeting brought together most of the people whose research has been (and is) fundamental to the better understanding of the molecular mechanisms responsible for the passage of the cells through the different phases of the cell cycle, and of how these mechanisms are impaired in cancer cells.
Along with definition of the different aspects and molecules involved in processes such as phosphorylation, de-phosphorylation, binding, synthesis and so on, the utilization of mouse knock-out for the different proteins involved in this intricate mechanism helped to clarify the various functions of these proteins and the possible relationships among them.
Over 200 posters were presented by authors from different countries all over the world. The invited speakers who presented their work are listed in the Appendix. It is impossible to cite the work of everyone; in this commentary I will try to briefly summarize the work presented by the different speakers, referring the reader to recently published reviews, most of them by authors present at the meeting [1-9], for a comprehensive introduction and description of the state-of-the-art of the cyclin/cyclin-dependent kinases/cdk inhibitors network.
The first session, on control of cyclin-dependent kinases, covered various aspects, among which the inhibitors of cyclin-dependent kinases were of particular interest.
A first group of proteins of the INK4 family (encoding inhibitors of Gl phase-specific, D-type cyclins/ CDK4-CDK6 complexes) has been analyzed in detail. The best known, pl6INK4A, is thus far the only one for which a true tumor suppressor activity has been demonstrated. The gene encoding pl6 was recently reported to yield, by alternative splicing, a completely different protein, p!9 ARF (alternative reading frame), in which a shift in the frame changes the entire amino-acid sequence. The mRNA for this protein has an ubiquitous expression, and more data are needed to define the precise role of this alternatively-spliced protein.
There were three presentations on the characteristics of knock-out mice for pl6, p21 and p27, all inhibitors of the cyclin-dependent kinases. pl6-/-mice develop cancers from a wide spectrum of origin after six months, a picture resembling that of p53 knock-out mice. As already published, p21 knock-out mice did not develop cancer but cells from p21-/-have lost the ability to arrest in Gl after damage.
The p27-/-mice were found to be larger than normal and in their tissues the cells were smaller but more numerous, suggesting a role for p27 in the regulation of cell progression. Benign pituitary tumors were found in these mice.
Data were presented on the role of phosphatases (cdc25 A, B and C) in c-myc-induced apoptosis. It was shown that c-myc is able to transactivate cdc25A and B and that the increased expression of these phosphatases leads to apoptosis. Antisense oligonucleotides against cdc 25A and B are able to block c-myc-induced apoptosis, demonstrating that these phosphatases act downtstream from c-myc in this process.
Other talks were on evidence that peptide regions of p21 interact with cdks, cyclins or PCNA, and transfection with plasmids encoding short fragments of p21 was found to be able to arrest the growth of different cell lines.
The role of c-myc was the subject of several presentations and the title of one session. More information is available on the function of the mycmax complex and on how the mad protein binds max and inhibits the transcription regulated by the mycmax complex. Several proteins of the mad family have been cloned, and all of these are able to block cell transformation induced by c-myc and also to stop the cells in the Gl phase of the cell cycle. Members of this family of proteins probably have interchangeable roles, since
